Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of (D/C/F/TAF) Once Daily Fixed Dose Combination (FDC) Regimen in Newly Diagnosed, Antiretroviral Treatment-naive Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Receiving Care in a Test and Treat Model of Care [Phase 3]

View source ↗

Summary

Phase 3 study evaluating the efficacy and safety of the once-daily fixed-dose combination doravirine/lamivudine/emtricitabine/tenofovir alafenamide (D/C/F/TAF) …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hiv-1

Drugs mentioned

• Descovy (emtricitabine/tenofovir alafenamide)
• Emtriva (emtricitabine)
• Epivir (Lamivudine)
• PIFELTRO (doravirine)

Snippet

Sponsor: Janssen Scientific Affairs, LLC | Conditions: HIV-1 | Phase 3 | Status: COMPLETED | Results posted: 2020-01-07